RENB-HV-21

N/A

Report date: 2024/11/06 16:55:39

Base Information

Drug NameRENB-HV-21
Drug Alias NameNatural Killer (NK) and Gamma Delta T-Cells (GDT) ENOB-HV-21Gamma-Delta (γδ)T Cell Therapy ENOB-HV-21γδT Cell Therapy ENOB-HV-21Adaptive allogenic cell therapy (Renovaro Biosciences)Allogenic NK and GD-T Cell therapy +[10] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsNatural killer cell replacements
TargetsT-cell receptor
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRenovaro Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesRenovaro Biosciences IncSeraph Research Institute
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A